Ontuxizumab

Ontuxizumab
Monoclonal antibody
TypeWhole antibody
SourceChimeric/humanized hybrid (mouse/human)
TargetTEM1
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6532H10050N1726O2054S44
Molar mass147034.92 g·mol−1

Ontuxizumab[1] is a humanized rabbit monoclonal antibody[2] designed for the treatment of cancer. It binds to endosialin (TEM1 or CD248).[3]

Phase I trials are complete and the drug was granted orphan drug status by the FDA for sarcoma. It is currently in phase II trials for melanoma, colorectal cancer, sarcoma, and lymphoma.[4]

This drug was developed by Morphotek and Ludwig Institute for Cancer Research.[4]

References

  1. World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2).
  2. US 20100260769, Sass PM, Kline B, Nicolaides N, Grasso L, Harley S, "Endosialin binding molecules", published 2010-04-08, assigned to Morphotek Inc
  3. Kiyohara E, Donovan N, Takeshima L, Huang S, Wilmott JS, Scolyer RA, et al. (August 2015). "Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications". Cancer Microenvironment. 8 (2): 111–8. doi:10.1007/s12307-015-0168-8. PMC 4542822. PMID 26085332.
  4. 1 2 "Ontuxizumab". Adis Insight. Springer Nature Switzerland AG.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.